Morningside Venture Invests In Series A Round In US Gene Therapy Company

Login to View

Apic Bio, Inc., an American gene therapy company for treatment of rare genetic diseases, has raised US$40 million, led by Chinese early-stage venture capital group Morningside Venture Investments, according to a January 7 announcement.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in

China Money Network Subscription